Xin‐Yuan Zhao

Xin‐Yuan Zhao

Auto-generated profile, based on publicly available information

Xin‐Yuan Zhao

Laboratory of Metabolism and Aging, School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, No.66 Gongchang Road, Shenzhen, 518107, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
BWBei Wang
Bei Wang
AWArabella H. Wan
Arabella H. Wan
YXYu Xu
Yu Xu
RZRuo-Xin Zhang
Ruo-Xin Zhang
BZBen-Chi Zhao
Ben-Chi Zhao
QWQiao-ping Wang
Qiao-ping Wang
The “death cap”, Amanita phalloides, is the world’s most poisonous mushroom, responsible for 90% of mushroom-related fatalities. The most fatal component of the death cap is α-amanitin. Despite its lethal effect, the exact mechanisms of how α-amanitin poisons humans remain unclear, leading to no specific antidote available for treatment. Here we show that STT3B is required for α-amanitin toxicity and its inhibitor, indocyanine green (ICG), can be used as a specific antidote. By combining a genome-wide CRISPR screen with an in silico drug screening and in vivo functional validation, we discover that N-glycan biosynthesis pathway and its key component, STT3B, play a crucial role in α-amanitin toxicity and that ICG is a STT3B inhibitor. Furthermore, we demonstrate that ICG is effective in blocking the toxic effect of α-amanitin in cells, liver organoids, and male mice, resulting in an overall increase in animal survival. Together, by combining a genome-wide CRISPR screen for α-amanitin toxicity with an in silico drug screen and functional validation in vivo, our study highlights ICG as a STT3B inhibitor against the mushroom toxin.

11 December 2023 in Phytotherapy Research
Verified
Journal Article
Closed access
XZXin‐Yuan Zhao
Xin‐Yuan Zhao
JWJi‐Qiu Wang
Ji‐Qiu Wang
GNG. Gregory Neely
G. Gregory Neely
YSYan‐Chuan Shi
Yan‐Chuan Shi
QWQiao-ping Wang
Qiao-ping Wang

7 March 2025 in Advanced Science
Verified
Journal Article
Open access
XZXin‐Yuan Zhao
Xin‐Yuan Zhao
BZBen‐Chi Zhao
Ben‐Chi Zhao
HLHui‐Lin Li
Hui‐Lin Li
YLYing Liu
Ying Liu
BWBei Wang
Bei Wang
QWQiao-ping Wang
Qiao-ping Wang
Stimulating adipose tissue thermogenesis has emerged as a promising strategy for combating obesity, with uncoupling protein 1 (UCP1) playing a central role in this process. However, the mechanisms that suppress adipose thermogenesis and energy dissipation in obesity are not fully understood. This study identifies mitochondrial carrier homolog 2 (MTCH2), an obesity susceptibility gene, as a negative regulator of energy homeostasis across flies, rodents, and humans. Notably, adipose‐specific MTCH2 depletion in mice protects against high‐fat‐diet (HFD)‐induced obesity and metabolic disorders. Mechanistically, MTCH2 deficiency promotes energy expenditure by stimulating thermogenesis in brown adipose tissue (BAT) and browning of subcutaneous white adipose tissue (scWAT), accompanied by upregulated UCP1 protein expression, enhanced mitochondrial biogenesis, and increased lipolysis in BAT and scWAT. Using integrated RNA sequencing and proteomic analyses, this study demonstrates that MTCH2 is a key suppressor of thermogenesis by negatively regulating autophagy via Bcl‐2‐dependent mechanism. These findings highlight MTCH2's critical role in energy homeostasis and reveal a previously unrecognized link between MTCH2, thermogenesis, and autophagy in adipose tissue biology, positioning MTCH2 as a promising therapeutic target for obesity and related metabolic disorders. This study provides new opportunities to develop treatments that enhance energy expenditure.

1 January 2026 in The Journal Of Prevention of Alzheimer's Disease
Verified
Journal Article
Open access
JYJing Yang
Jing Yang
XZXinyuan Zhao
Xinyuan Zhao
YLYidan Liu
Yidan Liu
YCYangwei Cai
Yangwei Cai
YFYuhua Fan
Yuhua Fan
Plasma glial fibrillary acidic protein (GFAP), neurofilament light (NfL), phosphorylated tau217 (p-tau217), and the β-amyloid (Aβ) 42/40 ratio are emerging indicators of neuroinflammation, neurodegeneration, and AD-specific pathology, while their specific roles within Alzheimer's disease (AD) and cerebral small vessel disease (CSVD) comorbidity are not fully understood. Participants with normal cognition or mild cognitive impairment were drawn from the Alzheimer's Disease Neuroimaging Initiative database. Multivariable linear regression and linear mixed-effects models were employed to examine associations of baseline plasma biomarkers with neuropathological features and cognition. Furthermore, Cox proportional hazards models assessed the associations of plasma biomarkers with the risk of comorbid AD and CSVD. In total populations, elevated GFAP and p-tau217 were significantly associated with greater white matter hyperintensity (WMH) burden, hippocampal atrophy, cerebral Aβ burden, and cognitive decline at baseline and with progression over time (|β| = 0.007 to 1.670, p = 0.047 to <0.0001). Within disease-specific subgroups, GFAP, p-tau217, and Aβ42/40 ratio demonstrated associations with hippocampal atrophy or WMH progression in CSVD (|β| = 0.011 to 0.220, p = 0.046 to 0.010), whereas GFAP, NfL, p-tau217, and Aβ42/40 ratio were linked to hippocampal atrophy and/or WMH progression in typical AD (|β| = 0.013 to 0.191, p = 0.044 to 0.0002). For Cox proportional hazards models, p-tau217 demonstrated greater precision in predicting progression to the CSVD phenotype within the AD subgroup (Hazard ratios = 1.267 to 3.811, p = 0.046 to 0.034). These findings underscore the potential role of plasma biomarkers in elucidating the synergistic mechanisms underlying AD and CSVD comorbidity.

7 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
JYJing Yang
Jing Yang
XZXinyuan Zhao
Xinyuan Zhao
YLYidan Liu
Yidan Liu
YCYangwei Cai
Yangwei Cai
YFYuhua Fan
Yuhua Fan
TIThe Alzheimer'S Disease Neuroimaging Initiative
The Alzheimer'S Disease Neuroimaging Initiative
Background: Alzheimer disease pathology and cerebral small‐vessel disease frequently coexist in older adults, yet how their interaction influences early clinical progression remains poorly understood, particularly in individuals without dementia. We aimed to investigate how plasma Alzheimer disease biomarkers and white matter hyperintensities (WMHs) interact to influence cognitive trajectories and the risk of progression to cognitive impairment and dementia. Methods: We studied 463 nondemented participants from the ADNI (Alzheimer's Disease Neuroimaging Initiative). Linear mixed‐effects models assessed interactions between plasma biomarkers and WMHs on cognitive trajectories. Cox models examined incident cognitive impairment and dementia. Moderated mediation analyses explored potential biological pathways. Results: Among 463 participants, plasma phosphorylated tau 217 to β‐amyloid 42 ratio was the only biomarker that consistently interacted with WMHs across multiple stages of disease progression, including cognitive decline (Mini‐Mental State Examination: β=−0.05 [95% CI, −0.06 to −0.03]; executive function: β=−0.02 [95% CI, −0.03 to −0.01]; memory: β=−0.03 [95% CI, −0.04 to −0.02]; language: β=−0.03 [95% CI, −0.04 to −0.02]; visuospatial function: β=−0.02 [95% CI, −0.04 to −0.01]) and increased clinical risk (cognitive impairment: χ 2 =15.67, P =0.047; dementia: χ 2 =15.88, P =0.044). These interactive associations were most pronounced in cognitively normal individuals and men. Moderated mediation analyses indicated that plasma glial fibrillary acidic protein partially mediated the interaction between phosphorylated tau 217 to β‐amyloid 42 ratio and WMHs for executive function and language performance. Conclusions: These findings indicate that phosphorylated tau 217 to β‐amyloid 42 ratio and WMHs jointly contribute to clinical progression in nondemented individuals, with astrocytic activation potentially involved in this process.